Pay in 4 interest-free payments of $5.62 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
Vital and Health Statistics
This review explores the molecular interplay between chronic infections and host immunity, highlights next-generation nanomaterials for regenerative applications, and proposes a sustainable paradigm that bridges clinical effectiveness with environmental responsibility
Ruxolitinib (Opzelura) cream, a JAK inhibitor, is the first FDA-approved repigmentation therapy for non-segmental vitiligo (ages 12+)
Unruptured intracranial aneurysms: Development, rupture and preventive management
it indicates sustainable improvement
US$ 21.84
US$ 21.62
US$ 23.55
US$ 23.30
US$ 24.71
US$ 27.71
US$ 27.70
US$ 26.48
US$ 25.75
US$ 21.83
US$ 27.05
